https://www.cell.com/cell/fulltext/S0092-8674(23)00403-8 “#BNT162b4 encodes variant-conserved, immunogenic segments of the #SARSCoV2 #nucleocapsid, membrane, and ORF1ab proteins, targeting diverse #HLA alleles. BNT162b4 elicits polyfunctional #CD4+ and #CD8+ #Tcell responses from diverse #epitopes in animal models, alone or when co-administered with BNT162b2 while preserving spike-specific immunity. Importantly, we demonstrate that BNT162b4 protects hamsters from severe disease and reduces viral titers”

RT @BioNTech_Group@twitter.com

We and @pfizer@twitter.com started a Phase 1 trial for #BNT162b4 aimed at enhancing the breadth of t cell responses. This is part of our next generation #COVID19 vaccine candidate approach. Goal: potentially broaden and extend the duration of protection against COVID-19.

🐦🔗: https://twitter.com/BioNTech_Group/status/1593026610818846720